ABSTRACT
Immunomodulating drug tactivin was used for treatment of 29 IHD patients with low T-suppressor activity and high cell sensitization to apoprotein B-containing lipoproteins and with lipoprotein-antibody immune complex detected in the blood. Tactivin was injected subcutaneously in the dose 10 micrograms (5 injections for 12 days). Tactivin treatment normalized T-suppressor activity, lowered concentration of plasma lipoprotein-antibody immune complex and improved clinical course of IHD. The beneficial effect of tactivin was observed in 70% of patients during 2 months. 30% of patients needed a second course of treatment of recover normal immunological and clinical indices. The treatment with tactivin of IHD patients must be combined with application of routine antianginal drugs.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Myocardial Ischemia/drug therapy , Peptides/therapeutic use , Thymus Extracts/therapeutic use , Adult , Aged , Angina Pectoris/drug therapy , Angina Pectoris/immunology , Angina Pectoris/physiopathology , Angina, Unstable/drug therapy , Angina, Unstable/immunology , Angina, Unstable/physiopathology , Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Autoimmune Diseases/physiopathology , Hemodynamics/drug effects , Humans , Male , Middle Aged , Myocardial Ischemia/immunology , Myocardial Ischemia/physiopathology , Time FactorsABSTRACT
The efficacy of extracorporeal cryohemosorption was estimated in the treatment of atherosclerotic patients in terms of the autoimmune theory of the pathogenesis of this disease. There was a slight decrease in the plasma levels of total cholesterol and triglycerides, there was over 2-fold reduction in the plasma levels of fibrinogen and fibronectin. All major components of apo B-containing lipoproteins and immunoglobulin G were found as part of the cryoprecipitate. An extremely high concentration of lipid hydroperoxides in the precipitate suggest that cryoprecipitation removes not only autoimmune complexes, but highly-atherogenic peroxide-modified lipoproteins. The three-fold decrease in the levels of lipoprotein-antibody complexes resulted in lower atherogenicity of apo B-containing lipoproteins. It is suggested that the mechanism responsible for beneficial clinical action of cryohemosorption sessions is largely associated with the removal of autoimmune lipoprotein-antibody complexes and peroxide-modified apo B-containing lipoproteins than correction of lipid metabolism.
Subject(s)
Antigen-Antibody Complex , Arteriosclerosis/therapy , Autoantibodies/immunology , Hemoperfusion , Lipoproteins/immunology , Adult , Aged , Apolipoproteins/analysis , Arteriosclerosis/blood , Arteriosclerosis/immunology , Autoimmune Diseases , Cholesterol/blood , Evaluation Studies as Topic , Female , Fibrinogen/analysis , Fibronectins/analysis , Humans , Immunoglobulin G/immunology , Male , Middle Aged , Triglycerides/bloodABSTRACT
The interaction of mouse peritoneal and human pericardial macrophages with lipoprotein (LP)-antibody (Ab) immune complex isolated from the serum of ischemic heart disease (IHD) patients has been studied. It is shown that the Ab of the autoimmune complex belongs to IgG class, and the antigen is the LP with d less than 1.063 g/ml. Incubation of mouse peritoneal macrophages with such complex led to the activation of [14C]oleic acid incorporation into cholesteryl esters by 2.5-2.8-fold, in comparison with the experiments where macrophages were incubated with free apoprotein (apo) B-containing LP isolated from the same serum. Incubation of human pericardial macrophages with autologous LP-Ab immune complex led to the transformation of macrophages into foam cells. These data lead to the conclusion that formation of LP-Ab autoimmune complexes may play an important role in the formation of atherosclerotic lesions of the arteries.
